While rounding in the medical intensive care unit, a physician evaluates the laboratory profile of a 62-year-old woman being treated for septic shock secondary to a urinary tract infection. The patient has a 10-year history of focal impaired awareness seizures and takes oral phenytoin mg daily. Currently, she is mechanically ventilated, receiving a continuous norepinephrine infusion, and deeply sedated. The nursing staff reports no abnormal movements or clinical seizure activity over the past hours.
Laboratory results from this morning are compared to her admission baseline:
| Parameter | Admission (Day 1) | Current (Day 3) | Reference Range |
|---|---|---|---|
| Blood urea nitrogen | mg/dL | mg/dL | mg/dL |
| Serum creatinine | mg/dL | mg/dL | mg/dL |
| Serum albumin | g/dL | g/dL | g/dL |
| Total serum phenytoin | g/mL | g/mL | g/mL |
Which of the following is the most appropriate next step regarding the patient's antiseizure therapy?
- Obtain a free serum phenytoin concentrationAnswer
- BIncrease the maintenance dosage of phenytoin
- CAdminister an intravenous loading dose of fosphenytoin
- DDiscontinue phenytoin and initiate intravenous valproic acid
- EInitiate continuous video electroencephalography monitoring
Answer
The most appropriate next step is to obtain a free serum phenytoin concentration to accurately assess the pharmacologically active drug level.
The correct next step is to obtain a free serum phenytoin concentration. Phenytoin is a highly protein-bound drug (typically bound to serum albumin). In critically ill patients with severe hypoalbuminemia, the number of binding sites is reduced, leading to a precipitous decrease in the bound fraction of the drug. This causes the total serum phenytoin level to appear subtherapeutic. Additionally, in the setting of severe uremia (as seen with this patient's acute kidney injury, with a BUN of mg/dL), retained endogenous organic acids directly displace phenytoin from its remaining binding sites on albumin, further increasing the free (unbound, pharmacologically active) fraction of the drug. Because the patient is clinically stable from a neurologic standpoint with no seizure activity, the low total phenytoin level is almost certainly an artifact of decreased protein binding rather than true subtherapeutic dosing. The active, free phenytoin level is likely within or even above the therapeutic range ( g/mL). Increasing the dose without checking a free level could precipitate severe phenytoin toxicity, which manifests as arrhythmias, cardiovascular collapse, nystagmus, and ataxia. Therefore, the safest and most guideline-concordant monitoring step is to measure the free serum phenytoin concentration before making any therapeutic adjustments.
Step-by-Step Solution
Key Concept
In critically ill patients with severe hypoalbuminemia or uremia, total serum phenytoin levels may appear falsely subtherapeutic due to decreased protein binding capacity; a free phenytoin concentration must be checked before adjusting the dose.
Alternative Method
The expected active drug level can be estimated mathematically by correcting the total phenytoin concentration for hypoalbuminemia and end-stage renal disease using the modified Sheiner-Tozer equation: . Using this patient's values, her adjusted total phenytoin is mathematically estimated to be g/mL, indicating she is actually supratherapeutic despite a 'low' measured total level. However, direct measurement of the free level is the clinical gold standard.
Estimated Time:1m 30s